Designed for patients treated with Stallergenes Greer’s liquid sublingual AITs, the availability of iPUMP® followed a pilot phase conducted by Stallergenes Greer during which 92% of patients systematically used iPUMP® while taking their treatment.

With the launch of this technological innovation, both Aptar Digital Health and Stallergenes Greer are responding to two of the major challenges in the day-to-day management of AIT treatments non-adherence and premature discontinuation of treatment.

With iPUMP®, the patient experience in the management of AIT is simpler. Thanks to multiple functionalities, patients can closely monitor their adherence, thus optimizing their treatment outcomes,” said Sai Shankar, President of Aptar Digital Health. “This collaboration with a leading company in the field of AIT illustrates Aptar Digital Health’s ability to deliver innovative, effective, and easy-to-use solutions to improve the patient’s experience with their therapy.

iPUMP® features a connected pressure sensor that converts the force exerted into an audible signal as soon as the threshold is reached, which confirms that the treatment has been taken. An integrated timer marks the end of the daily dose as prescribed, and a visual cue confirms if the daily dose has been taken.

iPUMP® is connected to a mobile application of the same name, which gives direct access to the protocol prescribed by the doctor. iPUMP® helps patients improve compliance with their treatment to optimize its efficacy while offering a function for tracking intake history for precise medication monitoring.

During the pilot phase, 74% of patients under 15 years of age adopted iPUMP® to improve their compliance, and almost two-thirds of participants perceived the solution as a real support in taking their liquid sublingual AIT.
This development and launch of iPUMP® marks an important milestone in a longstanding partnership between Aptar Digital Health and Stallergenes Greer. Based on their proprietary software platform, iPUMP® confirms Aptar Digital Health’s status as a major player in digital health innovation, as well as its capabilities to develop hardware and software solutions to the benefit of both the patient and the medical community

Milan, 15 February 2021. PatchAi and Roche Italia aim together for the digital transformation of the Italian healthcare system with an innovative solution for patients affected by oncological diseases.

PatchAi, the Italian digital health startup that aims to improve clinical research through a focus on patient engagement, and Roche Italia, a major player in the pharmaceutical industry, announce the agreement about the PatchAi for Smart Health Companion (SHC hereinafter) platform for oncology patients, already available from July 2020.

With this dedicated Patient Support Programs (PSPs) solution, PatchAi also enters the area of standard care pathways. SHC is a modular platform used to deliver the Roche Patient Support Program called “Smart Health Companion” and currently it is available in Italy for patients with haemato-oncological conditions.

PatchAi for Smart Health Companion embeds a virtual assistant to engage patients in improving self-management of their health conditions, tracking and sharing daily diaries, managing therapy intake/adherence and generating valuable Real World Evidence via Co-PRO® (Conversational Reported Outcomes). Insights are collected and analyzed to improve patients’ experience, clinicians’ workflows and support care delivery.

The project represents a massive step in driving the digital transformation of Healthcare in Italy, paving the way in facilitating health system sustainability and optimizing healthcare delivery by ensuring patient engagement at every step. During the Covid-19 pandemic, global health systems have been heavily affected on a large scale, causing significant impediments to standard care pathways. For instance, the AIOM (Italian Association of Medical Oncology) reported a -30% drop in first visits for diagnosis and a -36% drop in physical visits during the Italian pandemic. With the adoption of SHC, healthcare professionals can count on a reliable digital telemedicine solution to assist their patients in real time through video consultations, to collect Patient Reported Outcomes and other valuable health data.

Preliminary data on patients enrolled in Clinical Research using PatchAi® platform shows a protocol adherence up to 95%, significantly higher than other digital solutions in the market today and up to 9 times higher than paper-based ones. This result highlights the demonstrated ability to support patients and clinical teams via a modular solution.

“We met PatchAi in 2019 at the Roche HealthBuilders Open Innovation program. Together with many public and private partners in the health ecosystem, we envisioned a solution enabling significant improvements in oncology and hematology care pathways. Our efforts led to SHC, the first digital health solution registered as a Medical Device and fully personalised for oncology and haematology patients in Italy. The evidence collected show the capacity to consolidate more experiential and clinical value for the patient with a positive contribution to the healthcare system sustainability. These are very important results that we are proud of. As a stakeholder of the health system, we will make SHC available to all our public and private customers”, says Elia Ganzi, Integrated Customer Management Director at Roche Italia.

“We are proud to have realized this project, working at the forefront and doing now what patients need next within the digital health space too. With this major achievement, we will work towards playing an active role in redefining and revolutionizing patient engagement within digital healthcare. To enable the transformation of the current health systems, we will be helping medical teams in rapidly and efficiently supporting patients and translate “patient centricity” into programs that demonstrate their reliability and effectiveness from a health-economic perspective based on data driven results”, affirms Alessandro Monterosso, PatchAi CEO and Co-Founder. “This large-scale project recognizes our efforts and our commitment to innovation and value-based outcomes. At PatchAi we strive to stay ahead of the curve by further investing in R&D, data-science, and scaling our solution on an international level”, he adds.